RI

RIBOMIC Inc.

Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.

4591 | T

Overview

Corporate Details

ISIN(s):
JP3974850004
LEI:
Country:
Japan
Address:
港区白金台3−16−13 白金台ウスイビル6階
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

RIBOMIC Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of aptamer therapeutics. The company utilizes its proprietary RiboART system, a unique platform technology, to generate first-in-class, molecularly targeted drugs using RNA aptamers. RIBOMIC's research and development pipeline focuses on addressing unmet medical needs in a range of therapeutic areas, including ophthalmic disorders, pain, fibrosis, bone diseases, and rare diseases. The company pursues its mission through internal drug development programs and strategic partnerships within the pharmaceutical industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 08:30
Registration Form
確認書
Japanese 8.0 KB
2025-11-12 08:30
Interim / Quarterly Report
半期報告書-第23期(2025/04/01-2026/03/31)
Japanese 261.6 KB
2025-07-23 08:45
Registration Form
有価証券届出書(組込方式)
Japanese 326.2 KB
2025-06-20 03:50
Registration Form
確認書
Japanese 7.9 KB
2025-06-20 03:49
Governance Information
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 22.3 KB
2025-06-20 03:43
Annual Report
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2024-11-13 02:14
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-11-13 02:13
Interim / Quarterly Report
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 207.6 KB
2024-06-26 04:47
AGM Information
臨時報告書
Japanese 22.7 KB
2024-06-26 04:45
Governance Information
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 22.1 KB
2024-06-26 04:44
Registration Form
確認書
Japanese 8.0 KB
2024-06-26 04:43
Annual Report
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 2.0 MB
2024-02-14 02:26
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-02-14 02:25
Quarterly Report
四半期報告書-第21期第3四半期(2023/10/01-2023/12/31)
Japanese 178.6 KB
2023-11-13 08:01
Report Publication Announcement
確認書
Japanese 7.9 KB

Automate Your Workflow. Get a real-time feed of all RIBOMIC Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RIBOMIC Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RIBOMIC Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Develops medical devices, diagnostics, nutritionals, and pharmaceuticals for global health.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900

Talk to a Data Expert

Have a question? We'll get back to you promptly.